A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma

Exclusion Criteria

• •Contraindication to Xolair therapy (e.g., patients who experienced a severe hypersensitivity reaction to Xolair)
• •Acute asthma exacerbation within the previous 2 weeks of screening requiring any of the following: initiation of systemic corticosteroids, increased doses of systemic corticosteroids from baseline, doubling of inhaled corticosteroids, emergency room visit, or hospitalization
• •Acute flare of significant systemic disease (e.g., infection, hematologic, renal, hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent hospitalization because of their disease within the previous 2 months
• •Use of an experimental drug within 30 days prior to study screening
• •Diagnosis of cystic fibrosis
• •For patients in the non-Xolair-treated cohort, any prior treatment with Xolair